Pharma

Regeneron REGN

REGENERON PHARMACEUTICALS, INC.Pharmaceutical PreparationsNY

Pipeline — registered trials by phase

A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)

— · Moderate to Severe Atopic Hand and Foot Dermatitis · Completed · est. 2022-08-31

A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

— · High Risk Smoldering Multiple Myeloma (HR-SMM) · Recruiting · est. 2033-07-27

Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema

— · Diabetic Macular Edema · Completed · est. 2013-01

Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)

— · Hypercholesterolemia · Completed · est. 2014-04-30

A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable

— · Atopic Dermatitis · Completed · est. 2017-01-04

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

— · Cutaneous Squamous Cell Carcinoma · Active Not Recruiting · est. 2028-01-07

Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

— · Cutaneous Squamous Cell Carcinoma (CSCC) · Recruiting · est. 2030-05-03

A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently

— · Paroxysmal Nocturnal Hemoglobinuria · Recruiting · est. 2030-01-18

Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)

— · Heterozygous Familial Hypercholesterolemia · Completed · est. 2014-05

A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment

— · Paroxysmal Nocturnal Hemoglobinuria · Active Not Recruiting · est. 2026-10-12

Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)

— · Eosinophilic Esophagitis (EoE) · Completed · est. 2022-06-02

Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)

— · Eosinophilic Esophagitis · Completed · est. 2021-09-09

A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

— · Advanced Non-Small Cell Lung Cancer · Active Not Recruiting · est. 2027-09-28

Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers

— · Venous Thromboembolism (VTE) · Recruiting · est. 2031-07-18

Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)

— · Hypercholesterolemia · Completed · est. 2014-04

A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults

— · Monogenic Obesity · Recruiting · est. 2027-06-18

Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)

— · Dermatitis, Atopic · Completed · est. 2021-07-08

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

— · Relapsed Refractory Multiple Myeloma (RRMM) · Recruiting · est. 2033-04-19

Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)

— · Macular Edema Secondary to Central Retinal Vein Occlusion · Completed · est. 2010-10

Source: ClinicalTrials.gov (trials where Regeneron is lead sponsor; 57 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.

SEC filings — insider trading forms excluded

8-K2026-10-06Current report (material event)
8-K2026-09-30Current report (material event)
N-PX2026-08-20N-PX
13F-HR2026-08-0713F-HR
10-Q2026-07-30Quarterly report
8-K2026-07-30Current report (material event)
8-K2026-07-06Current report (material event)
8-K2026-06-17Current report (material event)
13F-HR2026-05-0813F-HR
SCHEDULE 13G2026-04-30SCHEDULE 13G
10-Q2026-04-29Quarterly report
8-K2026-04-29Current report (material event)
ARS2026-04-24Annual report to holders
DEFA14A2026-04-24DEFA14A
DEF 14A2026-04-24Proxy statement
8-K2026-04-08Current report (material event)
SCHEDULE 13G/A2026-03-27SCHEDULE 13G/A
13F-HR2026-02-0613F-HR
10-K2026-02-04Annual report
8-K2026-01-30Current report (material event)
8-K2026-01-12Current report (material event)
13F-HR2025-11-0713F-HR
10-Q2025-10-28Quarterly report
8-K2025-10-28Current report (material event)
8-K2025-10-06Current report (material event)
SCHEDULE 13G/A2025-08-06SCHEDULE 13G/A
13F-HR2025-08-0113F-HR
10-Q2025-08-01Quarterly report
8-K2025-08-01Current report (material event)
8-K2025-06-18Current report (material event)
SCHEDULE 13G/A2025-06-05SCHEDULE 13G/A
13F-HR2025-05-0213F-HR
10-Q2025-04-29Quarterly report
8-K2025-04-29Current report (material event)
ARS2025-04-29Annual report to holders
DEFA14A2025-04-29DEFA14A
DEF 14A2025-04-29Proxy statement
SCHEDULE 13G/A2025-04-22SCHEDULE 13G/A
UPLOAD2025-04-17UPLOAD
PRE 14A2025-04-07PRE 14A

Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.